 |
Mesothelioma NewsThe Mesothelioma News Resource |
BLOOMFIELD, N.J., June 22 /PRNewswire-FirstCall/ — Alfacell Corporation (Nasdaq: ACEL) today provided an update on the status of the ongoing confirmatory Phase IIIb registration trial evaluating ONCONASE(R) (ranpirnase), the Company’s lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM):
Rolling New Drug Application (NDA) for the ONCONASE UMM indication: The Company has now […]
June 20, 2006
BRANFORD, Conn., June 20 /PRNewswire-FirstCall/ — CuraGen Corporation (Nasdaq: CRGN - News) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being […]
June 7, 2006
WASHINGTON — There is evidence asbestos can cause cancer of the larynx, the Institute of Medicine reported yesterday.
Asbestos has long been associated with lung cancer and mesothelioma, a rare cancer of the lining of the chest and abdomen.
The U.S. Senate asked the institute, an arm of the National Academy of Sciences, to look […]
ATLANTA–(BUSINESS WIRE)–Jun 5, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today preliminary data from a phase I study of ZIO-201 (isophosphoramide mustard-lysine) were presented at the 2006 American Society of Clinical Oncology Annual Meeting. These data support the Company’s premise that certain adverse events associated with ifosfamide, an approved cancer drug extensively used […]
June 5, 2006
New York, NY, USA | Jun 05, 2006 | The Ludwig Institute for Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types […]
ATLANTA, June 3 /PRNewswire-FirstCall/ — Exelixis, Inc. (NASDAQ: EXEL) announces that updated results from a Phase I trial of XL647 in patients with advanced solid malignancies were reported today. XL647 is an orally bioavailable small molecule inhibitor of HER2, EGFR, VEGFR and EphB4. Study results demonstrate that XL647 is well tolerated and shows evidence of […]